| Autor: |
Glaeser JD; 1 Orthopedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center , Los Angeles, California.; 2 Department of Orthopedics, Cedars-Sinai Medical Center , Los Angeles, California.; 3 Board of Governors Regenerative Medicine Institute , Cedars-Sinai Medical Center, Los Angeles, California., Salehi K; 1 Orthopedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center , Los Angeles, California.; 2 Department of Orthopedics, Cedars-Sinai Medical Center , Los Angeles, California.; 3 Board of Governors Regenerative Medicine Institute , Cedars-Sinai Medical Center, Los Angeles, California., Kanim LEA; 1 Orthopedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center , Los Angeles, California.; 4 Cedars-Sinai Spine Center, Cedars-Sinai Medical Center , Los Angeles, California., Sheyn D; 1 Orthopedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center , Los Angeles, California.; 2 Department of Orthopedics, Cedars-Sinai Medical Center , Los Angeles, California.; 3 Board of Governors Regenerative Medicine Institute , Cedars-Sinai Medical Center, Los Angeles, California.; 5 Department of Biomedical Sciences, Cedars-Sinai Medical Center , Los Angeles, California.; 6 Department of Surgery, Cedars-Sinai Medical Center , Los Angeles, California., NaPier Z; 1 Orthopedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center , Los Angeles, California.; 2 Department of Orthopedics, Cedars-Sinai Medical Center , Los Angeles, California., Behrens PH; 1 Orthopedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center , Los Angeles, California.; 2 Department of Orthopedics, Cedars-Sinai Medical Center , Los Angeles, California., Garcia L; 3 Board of Governors Regenerative Medicine Institute , Cedars-Sinai Medical Center, Los Angeles, California., Cuéllar JM; 2 Department of Orthopedics, Cedars-Sinai Medical Center , Los Angeles, California., Bae HW; 1 Orthopedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center , Los Angeles, California.; 2 Department of Orthopedics, Cedars-Sinai Medical Center , Los Angeles, California.; 4 Cedars-Sinai Spine Center, Cedars-Sinai Medical Center , Los Angeles, California. |
| Abstrakt: |
Recombinant human bone morphogenic protein-2 (BMP-2)-loaded absorbable collagen sponges (ACS) have been successfully used to enhance bone formation and to induce spinal fusion in humans. However, side effects, such as soft tissue edema and inflammation, have been reported. NEMO binding domain peptide (NBD) inhibits activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a central regulator of immune response. In this study, we investigated NBD's potential to reduce BMP-2-induced soft tissue inflammation without affecting BMP-2-mediated spinal fusion in rat. For evaluation of soft tissue inflammation, ACS containing BMP-2, BMP-2+NBD, NBD, or ACS only were implanted into intramuscular paraspinal sites of 32 rats. At day 2 postsurgery, edema formation at the implant sites was assessed using magnetic resonance imaging. T2-weighted relaxation time (T2-RT) values were increased in the BMP-2 group compared with BMP-2+NBD, NBD, and ACS groups. No difference in T2-RT values was detected between BMP-2+NBD versus NBD and ACS controls. Postsacrifice, histological analysis of the implant-surrounding zones showed increased mononuclear cell infiltration in the BMP-2 group compared with BMP-2+NBD and controls. The presence of BMP-2 increased relative NF-κB binding and gene expression of inflammatory markers, interleukin (IL)1β, IL6, IL18, and chemokine ligand (CCL)2 and CCL3 compared with controls. In the BMP-2+NBD group, cytokine expression was blocked. No differences were found between BMP-2+NBD and control groups. For evaluation of spinal fusion, posterolateral intertransverse lumbar fusion procedures were performed on 16 rats. ACS were loaded with BMP-2 or BMP-2+NBD. After sacrifice at week 12, microcomputed tomographic assessment of the fusion site detected a higher bone volume and reduced trabecular spacing in the BMP-2+NBD group compared with BMP-2. Histological analysis did not show any differences in newly formed bone microarchitecture. In summary, addition of NBD to BMP-2-loaded ACS reduces BMP-2-induced soft tissue edema formation and mononuclear cell infiltration, diminishes NF-κB binding, and thus blocks transcription of NF-κB-regulated cytokines in rat. Furthermore, NBD stimulates bone formation in BMP-2-mediated spinal fusion, possibly through crosstalk of the NF-κB pathway with other pathways. The results of this study might provide the basis to develop new therapeutic bone grafting approaches with combinatory administration of BMP-2 and NBD for spinal fusion. |
